Missed one of our webinars?
Valerie and Erin are joined by Kevin Phelan, PhD, regulatory consultant for our Prosetin team. Dr. Phelan discusses how his breadth of regulatory experience, which ranges from a 20+ year career at Pfizer to hands-on work with start-up biotechs, is helping us to think outside the box and accelerate Prosetin’s development.
Valerie and Erin are joined by Emily Lowry, PhD, Director of Internal Operations for THE CORE and one of the lead scientists on the Prosetin pre-clinical development team at Columbia. Dr. Lowry describes how THE CORE is improving our ability to identify and evaluate promising ALS therapies, and details the drug screening process and challenges overcome in developing Prosetin.
Erin and Valerie speak with Jinsy Andrews, MD, MSc, Director of Neuromuscular Clinical Trials at Columbia University, about impactful clinical trial design and Prosetin’s development.
Valerie and Erin speak with Dr. Matthew Harms about ALS genetics and how his expertise is critical to THE CORE’s efforts to develop novel precision medicines for ALS.
Erin and Valerie speak with Lauren Black, PhD about IND enabling studies, what this means for Prosetin, and important considerations when approaching drug development for life-altering diseases such as ALS.
Erin and Valerie speak with Amanda and Eric Stevens about their journey to becoming leading activists to #axeALS and how they formed Team Stevens Nation to battle the toughest fight of their lives—against ALS and against time.
Sandy Morris was diagnosed with ALS in January 2018. Sandy joins Erin and Valerie to discuss her work as an ALS expert & advocate with I AM ALS—from specific efforts to improve ALS drug development, to big goals toward making ALS a priority on this planet.
Erin and Valerie speak with Arie Zask, PhD about his experience as a medicinal chemist and his role in the discovery and development of Prosetin.
Valerie and Erin are joined by Project ALS President, Meredith Estess. In 1998, Meredith cofounded Project ALS to set forth a new paradigm for ALS research. Meredith speaks about how Project ALS transformed the ALS landscape, and the decision and plans to bring Prosetin to people with ALS.
Erin and Valerie speak to Joe Quinn, MS, the expert guiding Chemistry, Manufacturing, and Controls (CMC) for Prosetin. Joe explains what CMC actually means, how drug manufacturing and formulation evolves with clinical development, and how we’re approaching this process with Prosetin.
Valerie and Erin speak with Hynek Wichterle, PhD, an associate professor at Columbia University and co-scientific director of THE CORE. Dr. Wichterle discusses developing the “ALS in a Dish” cellular drug screening model that his lab used to discover Prosetin, and how we continue to push ALS drug development forward through THE CORE.
Valerie introduces co-host Erin Fleming and Erin’s role as Director of External Operations at the Project ALS Therapeutics Core at Columbia (THE CORE) where she oversees the day-to-day operations of Prosetin’s development.
Erin and Valerie speak with Emmy Award winning writer and comedian, Judy Gold, about her support of Project ALS and how she has raised awareness and critical funding for leading edge medical research as an ambassador for the organization.
Erin and Valerie speak with Alejandro (Alex) Chavez MD, PhD about the unique system he and his lab are developing in which drugs can be tested against multiple genetic mutations causing ALS, and even other neurodegenerative diseases like Alzheimer’s and Parkinson’s, in one screen.
Erin & Valerie speak with Dr. Emily Lowry about where we are with the Prosetin program, and provide an update on other research progressing through THE CORE – despite the impact of COVID-19.
Valerie and Erin speak with Nadia Sethi and Cali Orsulak who aided the I AM ALS Promising Therapies Committee in debuting ALS Signal: a tool designed to empower those living with ALS with information about clinical ALS research on a global scale.
Valerie & Erin chat with George Mentis, PhD about how he is now using his knowledge of neural degeneration and motor systems to lead the In Vivo Electrophysiology Unit of the Project ALS Therapeutics Core at Columbia where where he applies cutting edge technology to better characterize motor neuron dysfunction—and response to potential therapies—in ALS.
Valerie and Erin speak with Michele Stellato about her diagnosis, the strength of her community, and how she plans on being the best thing to ever happen to ALS.